Hutchmed has completed patient enrolment for the Sanovo phase 3 clinical trial, investigating the use of Orpathys (savolitinib) in combination with Tagrisso (osimertinib) as a first-line treatment for certain lung cancer patients in China. The final patient was enrolled on 18 August 2025.
The study is focused on people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours carry both an EGFR mutation and MET overexpression. These genetic alterations are known to drive resistance to existing targeted therapies.
Sanovo is comparing the combination of Orpathys and Tagrisso against Tagrisso alone, which is a current standard of care. Its primary endpoint is progression-free survival, with other measures including overall survival, response rates and safety.
The results from the trial are anticipated in the latter half of 2026 and could support a supplementary New Drug Application to China’s National Medical Products Administration if positive.
Co-developed by Hutchmed and AstraZeneca, Orpathys is already approved in China for certain lung cancers. Tagrisso is widely used for EGFR-mutated NSCLC globally.
